Revefenacin for the treatment of chronic obstructive pulmonary disease

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
   PubMed Web of Science ®Google Scholar
• Heron M. Deaths: leading causes for 2017. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2019.
   Google Scholar
• López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23.
   PubMed Web of Science ®Google Scholar
• Tashkin DP. A review of nebulized drug delivery in COPD. Int J Chron Obst Pulm Dis. 2016;11:2585–2596.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58(10):4131–4164.
   PubMed Web of Science ®Google Scholar
• Heo YA. Revefenacin: first global approval. Drugs. 2019;79(1):85–91.
   PubMed Web of Science ®Google Scholar
• Fox LM, Foushee JA, Jackson DJ, et al. Visual compatibility of common nebulizer medications with 7% sodium chloride solution. Am J Health Syst Pharm. 2011;68(11):1032–1035.
   PubMed Web of Science ®Google Scholar
• Douglas M. Glycopyrrolate (Lonhala Magnair) for treatment of chronic obstructive pulmonary disease. Am Fam Physician. 2019;99(10):643–648.
   PubMed Web of Science ®Google Scholar
• The Medical Letter on Drugs and Therapeutics. Revefenacin (Yupelri) for COPD. Med Lett Drugs Ther. 2019;61(1564):14–15.
   PubMed Web of Science ®Google Scholar
• Dhand R, Dolovich M, Chipps B, et al. The role of nebulized therapy in the management of COPD: evidence and recommendations. Chronic Obstr Pulm Dis. 2012;9(1):58–72.
   Google Scholar
• Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103–109.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343.
   PubMed Web of Science ®Google Scholar
• Mastrodicasa MA, Droege CA, Mulhall AM, et al. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opin Investig Drugs. 2017;26(2):161–174.
   PubMed Web of Science ®Google Scholar
• Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;208:317–341.
   PubMedGoogle Scholar
• Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018;6(3):e00400.
   PubMed Web of Science ®Google Scholar
• Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013;346(2):241–250.
   PubMed Web of Science ®Google Scholar
• Steinfeld T, Pulido-Rios MT, Chin K, et al. In vitro characterization of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator. American Thoracic Society International Conference Abstracts. San Diego, CA. (2009).
   Google Scholar
• Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018;48:71–79.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Yupelri (revefenacin) [package insert]. Morgantown, WV: Mylan Specialty L.P.; 2018.
   Google Scholar
• U.S. Food and Drug Administration. Lonhala Magnair (glycopyrrolate) [prescribing information]. Marlborough, MA: Sunovion Respiratory Development Inc; 2019 June.
   Google Scholar
• U.S. Food and Drug Administration. Seebri Neohaler (glycopyrrolate) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; 2018 January.
   Google Scholar
• U.S. Food and Drug Administration. Spiriva HandiHaler (tiotropium bromide) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; 2018 February.
   Google Scholar
• U.S. Food and Drug Administration. Spiriva Respimat (tiotropium bromide) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2019 March.
   Google Scholar
• U.S. Food and Drug Administration. Tudorza Pressair (aclidinium bromide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019 April.
   Google Scholar
• U.S. Food and Drug Administration. Incruse Ellipta (umeclidinium) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2019 October.
   Google Scholar
• Ferguson GT, Feldman G, Pudi KK, et al. Improvements in lung function with nebulized revefenacin in the treatment of patients with moderate to very severe COPD: results from two replicate phase III clinical trials. Chronic Obstr Pulm Dis. 2019;6(2):154–165.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, et al. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019; 6(4):321–331.
   Web of Science ®Google Scholar
• Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182.
   PubMedGoogle Scholar
• Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kerwin E, Sethi S, et al. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2019;153:38–43.
   PubMed Web of Science ®Google Scholar
• Siler T, Moran E, Yun J, et al. Tolerability and efficacy of revefenacin when administered with formoterol via nebulization. CHEST. 2019;156(4):A1160–61.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Feldman G, Sethi S, et al. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: evaluation in phase 3 clinical trials. Pulm Pharmacol Ther. 2019;57:101808.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335–371.
   PubMed Web of Science ®Google Scholar
• Ram FS, Brocklebank DM, Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;1:CD002170.
   PubMedGoogle Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2017;16(3):249–254.
   Google Scholar
• Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. Int J Chron Obstruct Pulmon Dis. 2016;11:597–602.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794.
   PubMed Web of Science ®Google Scholar
• Ganguly A, Das AK, Roy A, et al. Study of proper use of inhalational devices by bronchial asthma or COPD patients attending a tertiary care hospital. J Clin Diagn Res. 2014;8(10):HC04–7.
   PubMedGoogle Scholar
• Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360–1374.
   PubMedGoogle Scholar
• Patel M, Steinberg K, Suarez-Barcelo M, et al. Chronic obstructive pulmonary disease in post-acute/long-term care settings: seizing opportunities to individualize treatment and device selection. J Am Med Dir Assoc. 2017;18(6):553.e22.
   PubMed Web of Science ®Google Scholar
• Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68(13):1221–1232.
   PubMed Web of Science ®Google Scholar
• Torres-Sanchez I, Rodriguez-Alzueta E, Cabrera-Martos I, et al. Cognitive impairment in COPD: a systematic review. J Bras Pneumol. 2015;41(2):182–190.
   PubMed Web of Science ®Google Scholar
• Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2015;50(10):1313–1321.
   Google Scholar
• Standaert TA, Morlin GL, Williams-Warren J, et al. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest. 1998;114(2):577–586.
   PubMed Web of Science ®Google Scholar
• Prime D, Grant AC, Slater AL, et al. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, diskus inhaler, diskhaler inhaler, and turbuhaler inhaler. J Aerosol Med. 1999;12(2):75–84.
   PubMedGoogle Scholar
• Al-Showair RAM, Tarsin WY, Assi KH, et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395–2401.
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83.
   PubMed Web of Science ®Google Scholar
• Broeders MEAC, Molema J, Vermue NA, et al. In check dial: accuracy for diskus and turbuhaler. Int J Pharm. 2003;252:275–280.
   PubMedGoogle Scholar
• Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the in-check dial to identify these rates. Respir Med. 2003;97(2):181–187.
   PubMed Web of Science ®Google Scholar
• Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217–224.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, et al. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595.
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, et al. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the diskus(R) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174–179.
   PubMed Web of Science ®Google Scholar